<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04257474</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-20257</org_study_id>
    <nct_id>NCT04257474</nct_id>
  </id_info>
  <brief_title>Barriers to Screening Breast MRI Utilization Among Patients at Elevated Risk</brief_title>
  <acronym>B-SUPER</acronym>
  <official_title>Barriers to Screening Breast MRI Utilization Among Patients at Elevated Risk (B-SUPER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to develop an explanatory framework for breast MRI utilization to inform
      future interventions. The Health Services Utilization Model (HSUM) will guide the selection
      of specific participant-level factors for examination, including predisposing characteristics
      (knowledge, health/cultural beliefs), enabling resources (social support, cost/insurance
      coverage), and perceived need (perceived susceptibility, provider recommendation).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reporting receipt of MRI breast screening</measure>
    <time_frame>12 months</time_frame>
    <description>Participant-reported receipt of screening breast MRI in the last 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reporting receipt of mammogram</measure>
    <time_frame>12 months</time_frame>
    <description>Participant-reported receipt of breast cancer screening mammogram in the last 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reporting receipt of ultrasound</measure>
    <time_frame>12 months</time_frame>
    <description>Participant-reported receipt of breast cancer screening ultrasound in the last 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reporting receipt of chemoprevention</measure>
    <time_frame>12 months</time_frame>
    <description>Participant-reported receipt of chemoprevention in the last 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reporting receipt of genetic counseling/testing</measure>
    <time_frame>12 months</time_frame>
    <description>Participant-reported receipt of genetic counseling/testing in the last 12 months</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Assessing Health Services Utilization Model (HSUM)</arm_group_label>
    <description>150 women with a high lifetime breast cancer risk will be recruited from mammography and primary care clinics. Researchers will assess HSUM factors influencing screening breast MRI utilization. Results will identify participant-level HSUM factors significantly associated with screening outcomes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Qualitative Interviews</arm_group_label>
    <description>Researchers will randomly select 30 participants from group 1 and will use semi-structured qualitive interviews exploring factors impacting utilization of screening breast MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Self-Report Survey</intervention_name>
    <description>The self-report survey will be created using the Health Services Utilization Model (HSUM)</description>
    <arm_group_label>Assessing Health Services Utilization Model (HSUM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Qualitative Interviews</intervention_name>
    <description>Researchers will randomly select 30 participants from group 1 and will use semi structured qualitive interviews exploring factors impacting utilization of screening breast MRI</description>
    <arm_group_label>Qualitative Interviews</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women will be recruited from mammography and primary care clinics, community-based outreach
        events, or via Facebook
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to speak/read English

          -  Within 2 years of last screening mammogram

          -  Pathogenic BRCA1/2 mutations OR estimated lifetime risk â‰¥20% per the National Cancer
             Institute (NCI) Breast Cancer Risk Assessment Tool (BCRAT)

        Exclusion Criteria:

          -  Women who have received a prior diagnosis of breast cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>The lifetime risk for breast cancer in men is very low (1.2% for male BRCA1 mutation carriers and 6.8% for male BRCA2 mutation carriers).</gender_description>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Claire Conley, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire Conley, PhD</last_name>
    <phone>(813) 745-6483</phone>
    <email>Claire.Conley@moffitt.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Georgetown Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>McKenzie McIntyre</last_name>
      <email>McKenzie.McIntyre@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Susan T Vadaparampil, PhD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bethany L Niell, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Naomi C Brownstein, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pathogenic BRCA 1/2 Mutation</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

